Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q1 2016 call → NO我们根据提供的电话会议记录来判断。管理层是否描述了公司目前正处于一个明确的等待期,并且为此支付成本,而收益尚未到来,且等待的结束是一个具体的、临近的事件。 分析: - 关于CUDC-907:正在进行Phase 2试验,针对MYC改变的DLBCL患者。管理层提到已完成Phase 1入组,并观察到响应。Phase 2正在进行,但尚未有结果。这算是在支付成本(临床试验费用)等待结果,但结果时间未明确,且不是“等待期”的典型描述。 - 关于CA170:预计本季度进入临床,是首个口服检查点抑制剂。管理层说“later this quarter, we expect CA170 to become the world's first orally administered checkpoint targeting immunooncology drug candidate to enter the clinic.” 这表示即将进入临床,但尚未开始。公司正在为临床试验支付成本(研发费用),但收益(数据、批准)尚未到来。等待的结束是“进入临床”这个事件,但进入临床本身不是收益,而是开始测试。管理层没有明确说这是一个等待期,而是说正在推进。 - 关于Erivedge:已商业化,有收入。 - 财务方面:研发费用增加,因为临床试验和合作项目。 管理层是否明确表示公司正在为一个尚未产生收益的特定事件支付成本,且该事件临近?CA170进入临床是临近事件,但进入临床本身不是收益,而是开始测试。管理层没有说“我们正在支付成本等待CA170进入临床”,而是说“我们预计本季度进入临床”。这更像是一个即将到来的里程碑,但公司已经在为临床试验支付成本,而收益(数据、批准)更远。 另外,管理层提到“we have now completed the enrollment in the monotherapy arm of the Phase 1”等,这些是进展,不是等待期。 关键点:管理层是否描述了一个“公司正在支付成本,但收益尚未到来,且等待结束是具体事件”的情况?CA170进入临床是具体事件,但进入临床后还要进行试验,收益(批准)更远。而且管理层没有强调这是“等待期”,而是正常推进。 此外,没有提到任何“正在支付成本但尚未收益”的明确表述,比如“我们正在为即将到来的X支付成本”等。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.